\-\ Texto\\:\\ \ \(0\)\
\-\ gastrin\\ 1416\\ \\(nl\\ 0\\-42\\)\ \(0\)\
\-\ the\\ patient\\ is\\ scheduled\\ for\\ surgery\\.\ \(1\)\
\-\ on\\ ct\\,\\ gastrinomas\\ are\\ hypervascular\\ and\\ average\\ 3\\-4\\ cm\\ in\\ diameter\\.\\ \\ in\\ over\\ one\\-half\\ of\\ cases\\,\\ multiple\\ lesions\\ are\\ present\\.\\ \\ thickened\\ gastric\\ and\\ small\\ bowel\\ folds\\ may\\ be\\ present\\ from\\ increased\\ gastric\\ acid\\ secretion\\ and\\ malabsorption\\.\\ \\ approximately\\ 60\\%\\ of\\ patients\\ have\\ metastases\\ at\\ the\\ time\\ of\\ diagnosis\\,\\ most\\ often\\ to\\ the\\ liver\\ and\\ lymph\\ nodes\\.\ \(0\)\
\-\ islet\\ cell\\ tumors\\ typically\\ express\\ somatostatin\\ receptors\\,\\ making\\ them\\ amenable\\ to\\ octreoscan\\ imaging\\ where\\ they\\ demonstrate\\ abnormally\\ increased\\ uptake\\ of\\ the\\ radiotracer\\.\ \(0\)\
\-\ gastrinoma\ \(10\)\
\-\ ductal\\ adenocarcinoma\ \(2\)\
\-\ islet\\-cell\\ tumor\\:\\ insulinoma\\,\\ gastrinoma\\,\\ nonfunctioning\\,\\ glucagonoma\\,\\ somatostatinoma\\,\\ vipoma\ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ metastases\\:\\ melanoma\\,\\ renal\\ cell\\,\\ breast\\,\\ lung\\,\\ stomach\ \(0\)\
\-\ solid\\ and\\ papillary\\ epithelial\\ neoplasm\ \(0\)\
\-\ mimics\\:\\ peripancreatic\\ adenopathy\\,\\ adrenal\\ mass\\,\\ splenule\ \(0\)\
\-\ focal\\ pancreatitis\ \(1\)\
\-\ idiopathic\\ fibrosing\\ pancreatitis\ \(0\)\
\-\ pancreaticoblastoma\\:\\ children\ \(0\)\
\-\ acinar\\ cell\\ carcinma\ \(0\)\
\-\ 85\\ yo\\ male\\ w\\/\\ h\\/o\\ distant\\ rcc\\ s\\/p\\ rt\\ nephrectomy\\ now\\ w\\/\\ transaminitis\\.\ \(0\)\
\-\ this\\ was\\ a\\ rather\\ unusual\\ presentation\\ for\\ a\\ gastrinoma\\ in\\ that\\ there\\ were\\ no\\ mets\\ identified\\ by\\ imaging\\,\\ and\\ the\\ patient\\ had\\ no\\ complaints\\ of\\ elevated\\ gastrin\\ levels\\.\\ \\ unfortunately\\,\\ the\\ patient\\ had\\ poor\\ kidney\\ function\\ and\\ could\\ not\\ receive\\ iv\\ contrast\\,\\ limiting\\ the\\ ct\\ imaging\\.\\ \\ however\\,\\ with\\ the\\ positive\\ octreoscan\\ and\\ dramatically\\ increased\\ serum\\ gastrin\\ level\\,\\ the\\ pancreatic\\ head\\ mass\\ is\\ consistent\\ with\\ a\\ gastrinoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gastrinoma\\:\\ 0\\.11609518933451972\ \(0\)\
\-\ gastrin\\:\\ 0\\.09209781896090836\ \(0\)\
\-\ octreoscan\\:\\ 0\\.06712703506947565\ \(0\)\
\-\ pancreatitis\\:\\ 0\\.03874697552827609\ \(0\)\
\-\ w\\/\\:\\ 0\\.03664042801068278\ \(0\)\
\-\ 1416\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ 0\\-42\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ islet\\-cell\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ glucagonoma\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ somatostatinoma\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ splenule\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ pancreaticoblastoma\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ carcinma\\:\\ 0\\.03642776208250619\ \(0\)\
\-\ gastrinomas\\:\\ 0\\.033563517534737825\ \(0\)\
\-\ vipoma\\:\\ 0\\.033563517534737825\ \(0\)\
\-\ acinar\\:\\ 0\\.0318880418813983\ \(0\)\
\-\ transaminitis\\:\\ 0\\.0318880418813983\ \(0\)\
\-\ gastric\\:\\ 0\\.03155624917522631\ \(0\)\
\-\ express\\:\\ 0\\.030699272986969454\ \(0\)\
\-\ somatostatin\\:\\ 0\\.030699272986969454\ \(0\)\
\-\ receptors\\:\\ 0\\.030699272986969454\ \(0\)\
\-\ mimics\\:\\ 0\\.030699272986969454\ \(0\)\
\-\ metastases\\:\\ 0\\.030171342562338714\ \(0\)\
\-\ insulinoma\\:\\ 0\\.029777192196414868\ \(0\)\
\-\ nonfunctioning\\:\\ 0\\.02902379733362993\ \(0\)\
\-\ cell\\:\\ 0\\.02861455427580355\ \(0\)\
\-\ one\\-half\\:\\ 0\\.028386811053352005\ \(0\)\
\-\ amenable\\:\\ 0\\.027835028439201083\ \(0\)\
\-\ dramatically\\:\\ 0\\.027835028439201083\ \(0\)\
\-\ malabsorption\\:\\ 0\\.026912947648646497\ \(0\)\
\-\ peripancreatic\\:\\ 0\\.026912947648646497\ \(0\)\
\-\ fibrosing\\:\\ 0\\.026912947648646497\ \(0\)\
\-\ secretion\\:\\ 0\\.026159552785861562\ \(0\)\
\-\ increased\\:\\ 0\\.02591510060082218\ \(0\)\
\-\ islet\\:\\ 0\\.025522566505583634\ \(0\)\
\-\ imaging\\:\\ 0\\.024819096997383504\ \(0\)\
\-\ limiting\\:\\ 0\\.02404870310087813\ \(0\)\
\-\ rcc\\:\\ 0\\.02384709085224411\ \(0\)\
\-\ rt\\:\\ 0\\.022964553247706677\ \(0\)\
\-\ \\,\\:\\ 0\\.02237273268737912\ \(0\)\
\-\ nl\\:\\ 0\\.022106539343664345\ \(0\)\
\-\ them\\:\\ 0\\.02161983258475367\ \(0\)\
\-\ epithelial\\:\\ 0\\.02150661368314989\ \(0\)\
\-\ folds\\:\\ 0\\.021396414315041787\ \(0\)\
\-\ hypervascular\\:\\ 0\\.02088561284410304\ \(0\)\
\-\ receive\\:\\ 0\\.02079061483491007\ \(0\)\
\-\ 3\\-4\\:\\ 0\\.020697751794199085\ \(0\)\
\-\ acid\\:\\ 0\\.020697751794199085\ \(0\)\
\-\ average\\:\\ 0\\.020606929865609105\ \(0\)\
\-\ distant\\:\\ 0\\.020606929865609105\ \(0\)\
\-\ mets\\:\\ 0\\.020345860024197818\ \(0\)\
\-\ unfortunately\\:\\ 0\\.020262377762555173\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.020021597150472633\ \(0\)\
\-\ 85\\:\\ 0\\.019720938661702266\ \(0\)\
\-\ making\\:\\ 0\\.019578433801904046\ \(0\)\
\-\ abnormally\\:\\ 0\\.0194406799991454\ \(0\)\
\-\ \\:\\:\\ 0\\.018682228363482066\ \(0\)\
\-\ h\\/o\\:\\ 0\\.01842483304659879\ \(0\)\
\-\ melanoma\\:\\ 0\\.01802136829633467\ \(0\)\
\-\ papillary\\:\\ 0\\.0179263702871417\ \(0\)\
\-\ adrenal\\:\\ 0\\.017879677910059334\ \(0\)\
\-\ scheduled\\:\\ 0\\.017787846766320864\ \(0\)\
\-\ pancreatic\\:\\ 0\\.017275989403871334\ \(0\)\
\-\ unusual\\:\\ 0\\.01708011238364578\ \(0\)\
\-\ serum\\:\\ 0\\.01704202703197254\ \(0\)\
\-\ rather\\:\\ 0\\.01678482740851295\ \(0\)\
\-\ ductal\\:\\ 0\\.01664473835200187\ \(0\)\
\-\ radiotracer\\:\\ 0\\.01647605242423222\ \(0\)\
\-\ idiopathic\\:\\ 0\\.016097262389001544\ \(0\)\
\-\ present\\:\\ 0\\.01595048556968331\ \(0\)\
\-\ nodes\\:\\ 0\\.015949137877542305\ \(0\)\
\-\ poor\\:\\ 0\\.015891343489216933\ \(0\)\
\-\ thickened\\:\\ 0\\.015834346290322984\ \(0\)\
\-\ adenopathy\\:\\ 0\\.015722657561447282\ \(0\)\
\-\ stomach\\:\\ 0\\.015613908353524254\ \(0\)\
\-\ 60\\:\\ 0\\.015404636730306258\ \(0\)\
\-\ complaints\\:\\ 0\\.015328813843247593\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.015254357208939005\ \(0\)\
\-\ children\\:\\ 0\\.015254357208939005\ \(0\)\
\-\ had\\:\\ 0\\.015238428258187671\ \(0\)\
\-\ function\\:\\ 0\\.014969262698662347\ \(0\)\
\-\ diameter\\:\\ 0\\.014856043797058568\ \(0\)\
\-\ s\\/p\\:\\ 0\\.014811610773189716\ \(0\)\
\-\ levels\\:\\ 0\\.014575418980462659\ \(0\)\
\-\ where\\:\\ 0\\.014411744856102963\ \(0\)\
\-\ lymph\\:\\ 0\\.014254307474977879\ \(0\)\
\-\ solid\\:\\ 0\\.014084077076472643\ \(0\)\
\-\ uptake\\:\\ 0\\.014028857126835588\ \(0\)\
\-\ tumors\\:\\ 0\\.013263290734175624\ \(0\)\
\-\ breast\\:\\ 0\\.013027098941448564\ \(0\)\
\-\ could\\:\\ 0\\.013027098941448564\ \(0\)\
\-\ iv\\:\\ 0\\.012886053460583032\ \(0\)\
\-\ they\\:\\ 0\\.01272291787804672\ \(0\)\
\-\ identified\\:\\ 0\\.01261763240159637\ \(0\)\
\-\ typically\\:\\ 0\\.012464569295479224\ \(0\)\
\-\ kidney\\:\\ 0\\.01243960105392566\ \(0\)\
\-\ liver\\:\\ 0\\.012174469053027784\ \(0\)\
\-\ presentation\\:\\ 0\\.012162812539219348\ \(0\)\
\-\ now\\:\\ 0\\.012070725577279536\ \(0\)\
\-\ neoplasm\\:\\ 0\\.012025440396330281\ \(0\)\
\-\ elevated\\:\\ 0\\.011980646121318442\ \(0\)\
\-\ cases\\:\\ 0\\.011763681256120382\ \(0\)\
\-\ positive\\:\\ 0\\.011458204918529408\ \(0\)\
\-\ often\\:\\ 0\\.011266419621982035\ \(0\)\
\-\ bowel\\:\\ 0\\.011074188152416361\ \(0\)\
\-\ approximately\\:\\ 0\\.010924867051882574\ \(0\)\
\-\ yo\\:\\ 0\\.010625419517780009\ \(0\)\
\-\ patient\\:\\ 0\\.010618908234500677\ \(0\)\
\-\ renal\\:\\ 0\\.01060940309693417\ \(0\)\
\-\ lung\\:\\ 0\\.01022793024892044\ \(0\)\
\-\ level\\:\\ 0\\.010177227386970793\ \(0\)\
\-\ lymphoma\\:\\ 0\\.010091729894171429\ \(0\)\
\-\ focal\\:\\ 0\\.010084684314621496\ \(0\)\
\-\ head\\:\\ 0\\.010014881448652464\ \(0\)\
\-\ time\\:\\ 0\\.009973558790245094\ \(0\)\
\-\ ct\\:\\ 0\\.009878542590016883\ \(0\)\
\-\ however\\:\\ 0\\.00983209940329368\ \(0\)\
\-\ mass\\:\\ 0\\.009821991792955079\ \(0\)\
\-\ are\\:\\ 0\\.009627056797765304\ \(0\)\
\-\ cm\\:\\ 0\\.00947089304883052\ \(0\)\
\-\ lesions\\:\\ 0\\.009452729365057635\ \(0\)\
\-\ patients\\:\\ 0\\.009138738013909197\ \(0\)\
\-\ over\\:\\ 0\\.008990258636941995\ \(0\)\
\-\ consistent\\:\\ 0\\.008658257309219848\ \(0\)\
\-\ surgery\\:\\ 0\\.0085743762990094\ \(0\)\
\-\ \\%\\:\\ 0\\.008236863774157057\ \(0\)\
\-\ tumor\\:\\ 0\\.008232364882689303\ \(0\)\
\-\ most\\:\\ 0\\.00815221132945486\ \(0\)\
\-\ small\\:\\ 0\\.008134608613145118\ \(0\)\
\-\ demonstrate\\:\\ 0\\.00812583529476463\ \(0\)\
\-\ diagnosis\\:\\ 0\\.008108344342067851\ \(0\)\
\-\ were\\:\\ 0\\.00801771213508232\ \(0\)\
\-\ contrast\\:\\ 0\\.00790403176366903\ \(0\)\
\-\ may\\:\\ 0\\.007745158549165801\ \(0\)\
\-\ have\\:\\ 0\\.0076464383403516195\ \(0\)\
\-\ multiple\\:\\ 0\\.007437214890410202\ \(0\)\
\-\ no\\:\\ 0\\.007111108683502496\ \(0\)\
\-\ male\\:\\ 0\\.006385146850774683\ \(0\)\
\-\ that\\:\\ 0\\.00609909391966456\ \(0\)\
\-\ for\\:\\ 0\\.006025687178865415\ \(0\)\
\-\ and\\:\\ 0\\.005950710933296478\ \(0\)\
\-\ by\\:\\ 0\\.005879631831590392\ \(0\)\
\-\ be\\:\\ 0\\.0054452757162972276\ \(0\)\
\-\ there\\:\\ 0\\.005255022960599127\ \(0\)\
\-\ from\\:\\ 0\\.005233205426257076\ \(0\)\
\-\ in\\:\\ 0\\.005223932605044483\ \(0\)\
\-\ the\\:\\ 0\\.005141502323688563\ \(0\)\
\-\ not\\:\\ 0\\.005102556494801386\ \(0\)\
\-\ a\\:\\ 0\\.0049165264688256355\ \(0\)\
\-\ at\\:\\ 0\\.0047841452596348475\ \(0\)\
\-\ is\\:\\ 0\\.004647031226320046\ \(0\)\
\-\ was\\:\\ 0\\.004083791414106144\ \(0\)\
\-\ this\\:\\ 0\\.003971641377331129\ \(0\)\
\-\ to\\:\\ 0\\.0035294884995288123\ \(0\)\
\-\ on\\:\\ 0\\.0029912851750637523\ \(0\)\
\-\ \\(\\:\\ 0\\.0029849658109250437\ \(0\)\
\-\ \\)\\:\\ 0\\.002948502859972335\ \(0\)\
\-\ of\\:\\ 0\\.0024071033222724885\ \(0\)\
\-\ \\.\\:\\ 0\\.001466922979229185\ \(0\)\
\-\ with\\:\\ 0\\.0009669766618999152\ \(0\)\
